Insulet Co. (NASDAQ:PODD) Receives Average Recommendation of “Buy” from Analysts

Shares of Insulet Co. (NASDAQ:PODDGet Rating) have been assigned a consensus rating of “Buy” from the seventeen research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $292.77.

Several equities analysts have issued reports on the stock. Raymond James dropped their price objective on shares of Insulet from $329.00 to $280.00 and set an “outperform” rating on the stock in a research note on Thursday, February 24th. StockNews.com initiated coverage on shares of Insulet in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Bank of America initiated coverage on shares of Insulet in a research note on Wednesday, March 2nd. They set a “buy” rating on the stock. Oppenheimer raised shares of Insulet from a “market perform” rating to an “outperform” rating and lowered their price target for the stock from $300.00 to $275.00 in a research note on Monday, January 31st. Finally, Morgan Stanley lowered their price target on shares of Insulet from $300.00 to $268.00 and set an “equal weight” rating on the stock in a research note on Friday, February 25th.

Shares of NASDAQ:PODD traded up $6.16 during trading on Friday, hitting $196.19. 8,146 shares of the company were exchanged, compared to its average volume of 614,065. The stock has a market capitalization of $13.60 billion, a P/E ratio of 302.34 and a beta of 0.72. The company has a debt-to-equity ratio of 3.11, a current ratio of 5.98 and a quick ratio of 4.51. Insulet has a 12-month low of $181.00 and a 12-month high of $324.81. The firm’s 50 day moving average price is $242.97 and its 200-day moving average price is $257.39.

Insulet (NASDAQ:PODDGet Rating) last released its quarterly earnings results on Thursday, May 5th. The medical instruments supplier reported $0.40 EPS for the quarter, beating the consensus estimate of $0.23 by $0.17. Insulet had a net margin of 3.91% and a return on equity of 15.81%. The firm had revenue of $295.40 million during the quarter, compared to the consensus estimate of $287.99 million. The business’s revenue for the quarter was up 17.1% on a year-over-year basis. As a group, equities research analysts anticipate that Insulet will post 1.31 EPS for the current year.

In related news, CFO Wayde D. Mcmillan sold 1,455 shares of the firm’s stock in a transaction on Friday, April 1st. The stock was sold at an average price of $275.60, for a total transaction of $400,998.00. Following the transaction, the chief financial officer now directly owns 21,354 shares in the company, valued at $5,885,162.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Shacey Petrovic sold 15,000 shares of the firm’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $273.25, for a total value of $4,098,750.00. Following the transaction, the chief executive officer now owns 13,607 shares in the company, valued at $3,718,112.75. The disclosure for this sale can be found here. 0.90% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Worldquant Millennium Advisors LLC bought a new stake in shares of Insulet during the first quarter valued at about $8,662,000. Walleye Capital LLC purchased a new position in Insulet in the 1st quarter worth about $544,000. Wealthfront Advisers LLC purchased a new position in Insulet in the 1st quarter worth about $439,000. Meiji Yasuda Life Insurance Co increased its stake in Insulet by 4.2% in the 1st quarter. Meiji Yasuda Life Insurance Co now owns 4,144 shares of the medical instruments supplier’s stock worth $1,104,000 after purchasing an additional 168 shares in the last quarter. Finally, Quantamental Technologies LLC purchased a new position in Insulet in the 1st quarter worth about $917,000.

About Insulet (Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

See Also

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.